
Prostate Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
Research To Practice | Oncology Videos
00:00
PARP Use in mCRPC: Practical Choices
Matthew prefers olaparib monotherapy for mCRPC BRCA-mutant disease; talazoparib possible with continued ARPI.
Play episode from 45:54
Transcript


